Mirvie

We’re so excited to announce Aimee Corso is joining the Mirvie executive team as Senior Vice President of Growth! Recognized for advancing patient engagement and empowerment in healthcare by creating a more patient-centric view of healthcare delivery, she will lead the launch of Mirvie’s first test using RNA to predict pregnancy complications months in advance 🚀🔬🤰 Welcome to the team, Aimee! Read more here: https://lnkd.in/g55hkMPc #pregnancyhealth #womenshealth #maternalhealth

“Hopefully, in the not-so-distant future, we can catch up and women’s health can be just health, in sync with other areas of medicine.” Mirvie CEO and co-founder Maneesh Jain shares how the provider aims to close critical knowledge gaps in women’s healthcare through its RNA platform — https://bit.ly/3D96Nno

We’re at an inflection point in #womenshealth. The first wave of startups in the field have focused on scaling digital access to care and normalized discussions focused on tremendous unmet needs in #fertility care access, family planning, and menopause care to support women throughout their lives. Building on this foundation, a new crop of startups like Mirvie and Gameto have invested in biological #research to advance the field and better serve women. We’re addressing the root causes of diseases rather than simply managing symptoms and accelerating breakthroughs that can help reverse the tide of the #maternalhealth crisis, improving the experience for women undergoing fertility treatments and understanding ovarian aging to better treat menopause. Read more in a new Fast Company op-ed by Mirvie CEO Maneesh Jain and Gameto CEO Dr. Dina Radenkovic (Turner) on how biology will catalyze breakthroughs in women’s health (link in comments).

Women’s health is at an inflection point, and the field has increased momentum to create much-needed breakthroughs in #pregnancyhealth, #menopause, and beyond. Naomi Kelman, seasoned healthcare executive and Mirvie board member, and Mirvie’s Maneesh Jain discuss opportunities to create new standards of care within #womenshealth and highlight innovation driving this forward. Read the conversation here: https://lnkd.in/gPsHmaXB

We are thrilled to welcome Dr. Thomas McElrath, MD, PhD as Vice President of Clinical Development and Dr. Lee Newcomer as Senior Advisor on Market Access to Mirvie. Renowned experts in their respective fields of maternal-fetal medicine and market access, Dr. McElrath and Dr. Newcomer will help Mirvie achieve the highest evidentiary standards and create healthier futures for moms and their families. Learn more about Mirvie’s newest executive team members (link in comments). #pregnancyhealth #womenshealth #maternalhealth

Breana’s story captures the silent epidemic stirring within the maternal health crisis. She was diagnosed with both #preeclampsia and placenta abruption at 33 weeks, which put both her and her baby’s life at risk. Delivering her son pre-term, Breana’s son spent the first 2 weeks of his life in the NICU. Upwards of 60,000 women like Breana nearly die from #pregnancy complications annually. The status quo isn’t working. Rates of preeclampsia - a leading cause of maternal morbidity - have doubled in the last 15 years. Severe maternal morbidity has also doubled over the past two decades. Understanding the “why” behind who’s most at risk for complications like preeclampsia is critical to help solve the #maternalhealth crisis. It’s time to bring pregnancy health into the era of precision medicine. If we can biologically understand who’s at risk early in pregnancy and apply preventive care to those identified as high risk, we have a significantly improved opportunity to prevent preeclampsia or mitigate the severity of the disease. Clinical tools like Mirvie’s test can identify who is most at-risk for preeclampsia, allowing pregnant women and their care team to take every action possible to create the healthiest pregnancy. Read more in a new op-ed in Fast Company from Mirvie CEO Maneesh Jain about the near-miss crisis within pregnancy health and why breakthrough solutions like Mirvie’s test are needed to shatter the status quo and create a new, better standard of care. Explore more at: https://lnkd.in/gbn6Dvjm

What’s the future of pregnancy health look like? Caltech's Techer details Mirvie CEO and co-founder Maneesh Jain’s journey to push the field of pregnancy health into the 21st century by using #RNA to predict pregnancy complications months in advance. Read more on how Mirvie is modernizing #maternalhealth here: https://lnkd.in/gUqQs-89

There's a clear societal need and sound business case for investing in #maternalhealth. The status quo isn’t working as rates of pregnancy complications like preeclampsia and severe maternal morbidity continue to rise. Forward-thinking investors like Khosla Ventures are supporting companies like Mirvie to usher in a new era of #pregnancy health. Breakthrough tools like Mirvie’s test, which uses #RNA to predict pregnancy complications like #preeclampsia, can help reverse the maternal health crisis in concert with novel approaches to maternal care. Read more in Reuters on the compelling, untapped opportunity for #investors to prioritize funding maternal health technologies and breakthroughs: https://lnkd.in/d97WdjCX

The maternal health crisis raging through America is not going to end anytime soon without serious changes. Thank you Reuters and Amina N. for shining a light on this critical topic and the outstanding opportunity for investment, innovation and impact. It shocks so many people to hear that pregnancy is more dangerous today than it was 20 years ago. That is absolutely unacceptable, and as Khosla Ventures' Alex Morgan said to Reuters, "Saving the lives of mothers and babies is in everyone's interest." KV's strategy on investing in maternal health technologies vs. clinics will be an integral part of solving the maternal health crisis. Breakthroughs in biological innovation and tech like Mirvie's #RNA platform can help reverse the tide of this crisis, in concert with novel approaches to maternal care. Let's not let this article, and moment, pass by without action. There is a compelling, untapped opportunity for investors to prioritize funding maternal health technologies and breakthroughs; for entrepreneurs and founders to become part of the solution; and for researchers to push forward the frontiers of our limited knowledge of maternal health. 

We need more #womenshealth at SXSW! Take a minute to vote for Mirvie alongside Gameto, Frida and Ingeborg Investments to speak about the urgency of accelerating innovation targeting unmet needs in women's health. Voting ends Sunday, August 18 so cast yours today: https://lnkd.in/eTjNbQ6B